Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL38658497 | 1.00 | ALDH1A1 (0.54) | ALDH1A1HTTCYP1A2CYP2C19CYP2C9 | |
| SCHEMBL382603 | 0.85 | ALDH1A1 (0.55) | ALDH1A1HTTCYP1A2CYP2C19CYP2C9 | |
| SCHEMBL31128806 | 0.84 | TDP1 (0.43) | ALDH1A1CYP1A2CYP2C19CYP2C9CYP2D6 | |
| SCHEMBL11727080 | 0.84 | ALDH1A1 (0.49) | ALDH1A1HTTCYP1A2CYP2C19CYP2C9 | |
| SCHEMBL9834668 | 0.83 | RAB9A (0.48) | ALDH1A1HTTCYP1A2CYP2C19CYP2D6 | |
| SCHEMBL1242300 | 0.81 | GPR35 (0.51) | ALDH1A1HTTCYP1A2CYP2C19CYP2C9 | |
| SCHEMBL2766810 | 0.81 | KCNJ11 (0.48) | ALDH1A1CYP1A2CYP2C19CYP2C9CYP2D6 | |
| SCHEMBL13483657 | 0.81 | MAPT (0.55) | ALDH1A1CYP1A2CYP2C19CYP2C9CYP2D6 | |
| SCHEMBL30603334 | 0.81 | SMN1; SMN2 (0.46) | ALDH1A1HTTCYP1A2CYP2C19CYP2C9 | |
| SCHEMBL1285934 | 0.81 | SMN1; SMN2 (0.46) | ALDH1A1HTTCYP1A2CYP2C19CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122036476-A | Preparation method of 4- (4-chlorophenoxy) -2-trifluoromethyl acetophenone | 江西天宇化工有限公司 | 2026-05-15 | — | — | CN | disclosed |
| WO-2011097491-A1 | BENZIMIDAZOLE ANTIVIRAL AGENTS | GLAXOSMITHKLINE LLC (US) | 2011-08-11 | — | — | WO | disclosed |
| CN-1209362-C | Tetrazolyl-phenyl acetamide glucokinase activators | HOFFMANN LA ROCHE (CH) | 2005-07-06 | — | — | CN | disclosed |
| EP-1311504-B1 | TETRAZOLYL-PHENYL ACETAMIDE GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004022534-A1 | ARYLGLYCINE DERIVATIVES FOR USE AS GLYCINE TRANSPORT INHIBITORS | NPS ALLELIX CORP. (CA) | 2004-03-18 | — | — | WO | disclosed |
| CN-1466584-A | Tetrazolyl-phenyl acetamide glucokinase activators | - | 2004-01-07 | — | — | CN | disclosed |
| EP-1311504-A1 | TETRAZOLYL-PHENYL ACETAMIDE GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-05-21 | — | — | EP | disclosed |
| US-6441180-B1 | TO INCREASE INSULIN SECRETION, WHICH MAKES THEM USEFUL FOR TREATING TYPE II DIABETES | HOFFMANN-LA ROCHE INC. | 2002-08-27 | — | — | US | disclosed |
| US-20020065275-A1 | Tetrazolyl-phenyl actamide glucokinase activators | SIDDURI ACHYUTHARAO (US) | 2002-05-30 | — | — | US | disclosed |
| US-6388088-B1 | ANTIDIABETIC AGENTS | HOFFMAN-LA ROCHE INC. | 2002-05-14 | — | — | US | disclosed |
| US-20020035267-A1 | Tetrazolyl-phenyl acetamide glucokinase activators | SIDDURI ACHYUTHARAO (US) | 2002-03-21 | — | — | US | disclosed |
| US-20020035266-A1 | Tetrazolyl-phenyl acetamide glucokinase activators | SIDDURI ACHYUTHARAO (US) | 2002-03-21 | — | — | US | disclosed |
| WO-2002014312-A1 | TETRAZOLYL-PHENYL ACETAMIDE GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-02-21 | — | — | WO | disclosed |
| EP-0470669-B1 | Preparation of fluorophenols, fluorohalophenols, N-acylfluoroanilines, and N-acylfluorohaloanilines | DOWELANCO (US) | 1997-11-12 | — | — | EP | disclosed |
| US-5622952-A | NERVOUS SYSTEM DISORDERS; ADMINISTERING 1,4-DIHYDROQUINOXALINE-2,3-DIONE | STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON, EUGENE OREGON (US) | 1997-04-22 | — | — | US | disclosed |
| US-5620979-A | TREATING NEURONAL LOSS ASSOCIATED WITH STROKE, ISCHEMIA, CENTRAL NERVOUS SYSTEM TRAUMA, HYPOGLYCEMIA OR SURGERY | STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON, EUGENE OREGON (US) | 1997-04-15 | — | — | US | disclosed |
| US-5514680-A | ANTICONVULSANTS WITH 5,6,7-TRISUBSTITUTED-1,4-DIHYDROQUINOXALINE-2,3-DIONE | THE STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY (US) | 1996-05-07 | — | — | US | disclosed |
| US-5164502-A | Fluorinating agents | DOWELANCO (US) | 1992-11-17 | — | — | US | disclosed |
| US-5116982-A | Fluorination | DOWELANCO (US) | 1992-05-26 | — | — | US | disclosed |
| EP-0470669-A2 | Preparation of fluorophenols, fluorohalophenols, N-acylfluoroanilines, and N-acylfluorohaloanilines | DOWELANCO (US) | 1992-02-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035267-A1 | Tetrazolyl-phenyl acetamide glucokinase activators | GCKR, GCK, PCK1 | ALDH1A1 2457/4885HTT 2555/4885CYP1A2 3105/4885 |
| US-20020035266-A1 | Tetrazolyl-phenyl acetamide glucokinase activators | GCKR, GCK, PCK1 | ALDH1A1 2457/4885HTT 2555/4885CYP1A2 3105/4885 |
| US-20020065275-A1 | Tetrazolyl-phenyl actamide glucokinase activators | GCKR, GCK, PFKL | ALDH1A1 3110/4885HTT 3205/4885CYP1A2 3440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.